Apogee Therapeutics (APGE) News Today

Apogee Therapeutics Inc. (NASDAQ: APGE) has been edging higher overall as shares trade near record levels, helped by takeover-related optimism, but sentiment is being tempered by analyst downgrades and insider selling.

• Positive Sentiment: Apogee’s proposed sale to AbbVie at $135.11 per share in cash continues to anchor valuation and support the stock, suggesting limited downside if the deal closes as expected. Article Title
• Neutral Sentiment: Stifel reiterated a Hold rating and raised its price target to $135, indicating the shares are already close to the deal value. Article Title
• Neutral Sentiment: Mizuho downgraded APGE from Outperform to Hold while lifting its target to $135, signaling less upside left even though the acquisition price remains supportive. Article Title
• Neutral Sentiment: CEO Michael Thomas Henderson and insider Carl Dambkowski sold shares under pre-arranged 10b5-1 plans, which may not be a major red flag but can still weigh on investor sentiment. Article Title Article Title
• Negative Sentiment: A law firm launched an investigation into whether the proposed sale price and process are adequate, adding legal and deal-closing uncertainty for shareholders. Article Title

Overall, APGE is being driven mainly by the AbbVie buyout near current trading levels, while the stock’s recent movement is likely being capped by analyst downgrades, insider selling, and questions around the transaction process.